GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 250
- Registration Number
- NCT01472198
- Locations
- 🇺🇸
UCLA Community Oncology Practice, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States
Gilead Sustained Virologic Response (SVR) Registry
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 6625
- Registration Number
- NCT01457755
- Locations
- 🇺🇸
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States
🇺🇸Methodist Dallas Medical Center, Dallas, Texas, United States
🇺🇸Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2018-05-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 570
- Registration Number
- NCT01457768
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Medical College of Wisconsin, Chicago, Illinois, United States
Pilot Study of Simtuzumab in the Treatment of Liver Fibrosis
- Conditions
- Liver Fibrosis
- Interventions
- Biological: Simtuzumab
- First Posted Date
- 2011-10-14
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT01452308
- Locations
- 🇺🇸
Weill Cornell Medical College: NewYork-Presbyterian Hospital, New York, New York, United States
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
- Conditions
- Coronary Artery DiseaseAngina Pectoris
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2016-07-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 2651
- Registration Number
- NCT01442038
- Locations
- 🇺🇸
Tallahassee Research Institute, Tallahassee, Florida, United States
🇺🇸Union Memorial Hospital, Baltimore, Maryland, United States
🇺🇸Veterans Administration Medical Center, Pittsburgh, Pennsylvania, United States
Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
- Conditions
- Acquired Immunodeficiency SyndromeHIV Infections
- Interventions
- First Posted Date
- 2011-09-26
- Last Posted Date
- 2016-12-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 314
- Registration Number
- NCT01440569
- Locations
- 🇺🇸
Gary J. Richmond,M.D., P.A., Fort Lauderdale, Florida, United States
🇺🇸Atlanta ID group, Atlanta, Georgia, United States
🇺🇸Mercer University, Macon, Georgia, United States
GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: placebo to match tegobuvirDrug: placebo to match RBV
- First Posted Date
- 2011-09-16
- Last Posted Date
- 2013-12-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 170
- Registration Number
- NCT01435226
- Locations
- 🇺🇸
Advanced Clinical Research Institute, LLC, Anaheim, California, United States
🇺🇸Lightsource Medical, Los Angeles, California, United States
🇺🇸Medical Associates Research Group, Inc., San Diego, California, United States
Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: Placebo to match sofosbuvirDrug: Placebo to match GS-0938
- First Posted Date
- 2011-09-15
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 239
- Registration Number
- NCT01435044
- Locations
- 🇺🇸
Advanced Research Institute, Trinity, Florida, United States
🇺🇸UCSD Antiviral Research Center, San Diego, California, United States
🇺🇸eStudy Site, San Diego, California, United States
GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection
- Conditions
- Chronic Genotype 1a or 1b HCV Infection
- Interventions
- Drug: GS-5885 tabletDrug: GS-9451 tabletDevice: placebo matching tegobuvir capsule
- First Posted Date
- 2011-09-15
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 163
- Registration Number
- NCT01434498
- Locations
- 🇺🇸
Kaiser Permanente Medical Center, Los Angeles, California, United States
🇺🇸Medical Associates Research Group, Inc., San Diego, California, United States
🇺🇸Kaiser Permanente, San Diego, California, United States
Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection
- Conditions
- Hepatitis C
- Interventions
- Drug: GS-9669 tabletsDrug: Placebo to Match GS-9669 tablet
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2012-07-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 82
- Registration Number
- NCT01431898
- Locations
- 🇺🇸
Avail Clinical Research, LLC, Deland, Florida, United States
🇺🇸Impact Clinical Trials, Las Vegas, Nevada, United States
🇺🇸University of Utah Health Sciences Center, Salt Lake City, Utah, United States